S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)
S&P 500   4,662.85 (+0.08%)
DOW   35,911.81 (-0.56%)

Summit Therapeutics Stock Forecast, Price & News

+0.03 (+1.27%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
97,529 shs
Average Volume
125,020 shs
Market Capitalization
$233.54 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SMMT News and Ratings via Email

Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Summit Therapeutics logo

About Summit Therapeutics

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$20.17 million
Book Value
$0.96 per share


Net Income
$-52.70 million
Net Margins
Pretax Margin




Free Float
Market Cap
$233.54 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.13 out of 5 stars

Medical Sector

1224th out of 1,417 stocks

Pharmaceutical Preparations Industry

587th out of 683 stocks

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Summit Therapeutics (NASDAQ:SMMT) Frequently Asked Questions

Is Summit Therapeutics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Summit Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Summit Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SMMT, but not buy additional shares or sell existing shares.
View analyst ratings for Summit Therapeutics
or view top-rated stocks.

How has Summit Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Summit Therapeutics' stock was trading at $1.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SMMT stock has increased by 26.5% and is now trading at $2.39.
View which stocks have been most impacted by COVID-19

Are investors shorting Summit Therapeutics?

Summit Therapeutics saw a increase in short interest in the month of December. As of December 15th, there was short interest totaling 514,600 shares, an increase of 26.3% from the November 30th total of 407,300 shares. Based on an average trading volume of 170,000 shares, the short-interest ratio is currently 3.0 days. Currently, 2.0% of the company's shares are sold short.
View Summit Therapeutics' Short Interest

When is Summit Therapeutics' next earnings date?

Summit Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 16th 2022.
View our earnings forecast for Summit Therapeutics

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics Inc. (NASDAQ:SMMT) posted its earnings results on Monday, November, 15th. The company reported ($0.20) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.29) by $0.09. The company earned $6.12 million during the quarter. Summit Therapeutics had a negative net margin of 424.58% and a negative trailing twelve-month return on equity of 82.11%.
View Summit Therapeutics' earnings history

Who are Summit Therapeutics' key executives?

Summit Therapeutics' management team includes the following people:
  • Mr. Robert W. Duggan, Exec. Chairman & CEO (Age 77) (LinkedIn Profile)
  • Mr. Michael Paul Donaldson, Chief Financial Officer (Age 44, Pay $296.2k)
  • Dr. Mahkam Zanganeh M.B.A., D.D.S., MBA, COO & Director (Age 51, Pay $459.38k)
  • Prof. Dame Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 71)
  • Dr. David Jonathan Powell, Chief Scientific Officer (Age 51)
  • Ms. Michelle Avery, Director of Investor Relations
  • Mr. Dave Gancarz, Head of Investor Relations & Corp. Strategy
  • Ms. Christine Armstrong, VP of Marketing?
  • Mr. Campbell Hair, Head of HR?
  • Dr. Jonathon Tinsley, Chief Scientific Officer of DMD (Age 62)

What other stocks do shareholders of Summit Therapeutics own?

When did Summit Therapeutics IPO?

(SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.

What is Summit Therapeutics' stock symbol?

Summit Therapeutics trades on the NASDAQ under the ticker symbol "SMMT."

How do I buy shares of Summit Therapeutics?

Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Summit Therapeutics' stock price today?

One share of SMMT stock can currently be purchased for approximately $2.39.

How much money does Summit Therapeutics make?

Summit Therapeutics has a market capitalization of $233.54 million and generates $20.17 million in revenue each year. The company earns $-52.70 million in net income (profit) each year or ($0.86) on an earnings per share basis.

How many employees does Summit Therapeutics have?

Summit Therapeutics employs 80 workers across the globe.

What is Summit Therapeutics' official website?

The official website for Summit Therapeutics is www.summitplc.com.

Where are Summit Therapeutics' headquarters?

Summit Therapeutics is headquartered at 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB.

How can I contact Summit Therapeutics?

Summit Therapeutics' mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 617-514-7149, via email at [email protected], or via fax at 44-12-3544-3999.

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.